JPWO2021069705A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021069705A5 JPWO2021069705A5 JP2022521718A JP2022521718A JPWO2021069705A5 JP WO2021069705 A5 JPWO2021069705 A5 JP WO2021069705A5 JP 2022521718 A JP2022521718 A JP 2022521718A JP 2022521718 A JP2022521718 A JP 2022521718A JP WO2021069705 A5 JPWO2021069705 A5 JP WO2021069705A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- branched
- membered
- pharmaceutically acceptable
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH12812019 | 2019-10-09 | ||
| CH01281/19 | 2019-10-09 | ||
| PCT/EP2020/078483 WO2021069705A1 (en) | 2019-10-09 | 2020-10-09 | Isoindolinone compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551185A JP2022551185A (ja) | 2022-12-07 |
| JPWO2021069705A5 true JPWO2021069705A5 (OSRAM) | 2023-10-17 |
| JP7724394B2 JP7724394B2 (ja) | 2025-08-18 |
Family
ID=68242216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521718A Active JP7724394B2 (ja) | 2019-10-09 | 2020-10-09 | イソインドリノン化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220242846A1 (OSRAM) |
| EP (1) | EP4041231A1 (OSRAM) |
| JP (1) | JP7724394B2 (OSRAM) |
| WO (1) | WO2021069705A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4076464A4 (en) * | 2019-12-17 | 2024-06-12 | Orionis Biosciences, Inc. | COMPOUNDS FOR MODULATION OF PROTEIN RECRUITMENT AND/OR DEGRADATION |
| US20240050428A1 (en) * | 2020-10-07 | 2024-02-15 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| WO2022153220A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Methods for the identification of degrons |
| CN117242060A (zh) * | 2021-01-13 | 2023-12-15 | 蒙特罗萨医疗公司 | 异吲哚啉酮化合物 |
| WO2022152822A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Treatment of myc-driven cancers with gspt1 degraders |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| EP4313047A1 (en) * | 2021-03-22 | 2024-02-07 | Monte Rosa Therapeutics, Inc. | Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons |
| US20240287573A1 (en) | 2021-06-04 | 2024-08-29 | Monte Rosa Therapeutics, Inc. | E3 ligase fusion proteins for proximity detection |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| CN117751112A (zh) * | 2021-07-19 | 2024-03-22 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
| WO2023069700A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069708A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and uses thereof |
| WO2023069720A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| US20250037790A1 (en) | 2021-11-17 | 2025-01-30 | Monte Rosa Therapeutics, Inc. | Degron and neosubstrate identification |
| US12187699B2 (en) | 2022-04-14 | 2025-01-07 | Bristol-Myers Squibb Company | GSPT1 compounds and methods of use of the novel compounds |
| EP4554581A1 (en) | 2022-07-13 | 2025-05-21 | Monte Rosa Therapeutics AG | Combination therapy comprising gspt1-directed molecular glue degraders and pi3k/akt/mtor pathway inhibitors |
| WO2024015565A1 (en) * | 2022-07-14 | 2024-01-18 | Monte Rosa Therapeutics, Inc. | Methods of preparing an isoindolinone derivative and crystal forms thereof |
| WO2024027795A1 (zh) * | 2022-08-04 | 2024-02-08 | 苏州开拓药业股份有限公司 | 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| IL319458A (en) | 2022-09-09 | 2025-05-01 | Innovo Therapeutics Inc | Compounds that reduce ck1α and dual ck1α/gspt1 |
| WO2024201248A1 (en) * | 2023-03-24 | 2024-10-03 | Pin Therapeutics, Inc. | Compounds and methods for degrading gspt1 |
| WO2025051180A1 (zh) * | 2023-09-06 | 2025-03-13 | 上海超阳药业有限公司 | 内酰胺类衍生物及其应用 |
| WO2025085416A1 (en) * | 2023-10-16 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1 compounds and methods of use of the compounds |
| WO2025146112A1 (en) * | 2024-01-05 | 2025-07-10 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Gspt1 degrading compounds and compositions and uses thereof |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| CL2007002513A1 (es) * | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| PE20140963A1 (es) * | 2008-10-29 | 2014-08-06 | Celgene Corp | Compuestos de isoindolina para el tratamiento de cancer |
| TWI696615B (zh) * | 2016-05-05 | 2020-06-21 | 瑞士商伊蘭科動物健康公司 | 雜芳基-1,2,4-三唑及雜芳基-三唑化合物 |
| EP3455219A4 (en) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| HUE070289T2 (hu) * | 2016-10-11 | 2025-05-28 | Arvinas Operations Inc | Vegyületek és módszerek az androgénreceptor célzott lebontására |
| EP3743066A4 (en) * | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| EP4126067A4 (en) * | 2020-03-31 | 2024-12-04 | Orum Therapeutics Inc. | NEODEGRADER CONJUGATES |
-
2020
- 2020-10-09 WO PCT/EP2020/078483 patent/WO2021069705A1/en not_active Ceased
- 2020-10-09 EP EP20789952.7A patent/EP4041231A1/en active Pending
- 2020-10-09 JP JP2022521718A patent/JP7724394B2/ja active Active
-
2022
- 2022-04-08 US US17/716,169 patent/US20220242846A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021069705A5 (OSRAM) | ||
| JP2021169499A5 (OSRAM) | ||
| JP2024050527A5 (OSRAM) | ||
| JP2020169171A5 (OSRAM) | ||
| JP2001526269A5 (OSRAM) | ||
| RU2020115095A (ru) | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 | |
| KR920009796A (ko) | 3-아미도인돌릴 유도체 | |
| CA2679232A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
| JPWO2019213318A5 (OSRAM) | ||
| JP2006501181A5 (OSRAM) | ||
| JP2014015465A5 (OSRAM) | ||
| RU2013130250A (ru) | Замещенные пуриновые и 7-деазапуриновые соединения | |
| JP2005526857A5 (OSRAM) | ||
| JP2019500315A5 (OSRAM) | ||
| RU2010112450A (ru) | Производные хиназолинона, полезные в качестве ванилоидных антагонистов | |
| JP2021046404A5 (OSRAM) | ||
| JP2006507355A5 (OSRAM) | ||
| JP2005536519A5 (OSRAM) | ||
| JP2011509302A5 (OSRAM) | ||
| JP2019528279A5 (OSRAM) | ||
| JPWO2022152821A5 (OSRAM) | ||
| JPWO2020023560A5 (OSRAM) | ||
| JPWO2019165358A5 (OSRAM) | ||
| RU92016234A (ru) | Производные 3(2н)-пиридазинона, способ их получения, применение, фармацевтическая композиция, способ лечения | |
| ATE24503T1 (de) | Phenylpiperazin-derivate und verfahren zu deren herstellung. |